Davidson Michael H, Maki Kevin C, Pearson Thomas A, Pasternak Richard C, Deedwania Prakash C, McKenney James M, Fonarow Gregg C, Maron David J, Ansell Benjamin J, Clark Luther T, Ballantyne Christie M
Radiant Development, Chicago, Illinois, USA.
Am J Cardiol. 2005 Aug 15;96(4):556-63. doi: 10.1016/j.amjcard.2005.04.019.
The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.
最近一次关于遵循国家胆固醇教育计划(NCEP)成人治疗专家组(ATP)指南情况的全国性调查是在ATP III发布之前完成的,结果显示低密度脂蛋白(LDL)胆固醇目标的达标情况很不理想。NCEP利用新型电子技术进行的评估项目(NEPTUNE)II是2003年开展的一项全国性调查。在4885名患者中,67%实现了LDL胆固醇治疗目标,其中在无或有1个危险因素、≥2个危险因素或冠心病(CHD)以及CHD风险等同类别中,分别有89%、76%和57%的患者达标。在每个风险类别中,甘油三酯浓度≥200mg/dl(2.25mmol/L)且实现LDL胆固醇和非高密度脂蛋白胆固醇目标的患者比例分别为64%、52%和27%。糖尿病患者(55%)和其他CHD风险等同患者(40%)相比CHD患者(62%)更不容易实现LDL胆固醇目标。在1447名心血管疾病患者中,根据2004年7月NCEP写作组的新建议,75%可被归类为极高危,而在这些极高危患者中,17.8%的患者LDL胆固醇水平<70mg/dl(<1.81mmol/L)。总之,这些结果表明与之前的调查相比,血脂管理有所改善。在2004年7月ATP III新增的项目中发现了最大的治疗差距,包括CHD风险等同患者的目标达成情况以及非高密度脂蛋白胆固醇目标。NEPTUNE II中大多数(75%)心血管疾病患者会被视为极高危,是积极治疗以达到新的可选治疗目标的候选对象。